Compare Stocks: LXRX, DNLI, RCUS, and AMLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$27.20 -0.8%	$30.26	$10.83 ▼ $41.14	$3.06B	-0.1	1.46 million shs	2.62 million shs
DNLI Denali Therapeutics	$18.67 -2.6%	$22.47	$13.75 ▼ $27.30	$3.06B	1.02	1.90 million shs	2.37 million shs
LXRX Lexicon Pharmaceuticals	$1.76	$2.15	$1.10 ▼ $2.68	$783.12M	1.07	3.37 million shs	3.32 million shs
RCUS Arcus Biosciences	$23.78 -3.0%	$27.58	$14.26 ▼ $31.74	$3.12B	0.94	1.77 million shs	1.86 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-2.18%	-5.74%	-19.56%	+49.24%	+103.34%
DNLI Denali Therapeutics	-0.62%	-7.31%	-14.00%	-29.58%	+28.59%
LXRX Lexicon Pharmaceuticals	+0.57%	-6.13%	-21.43%	-21.78%	+15.79%
RCUS Arcus Biosciences	+1.00%	-5.26%	-17.31%	-18.31%	+75.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$27.20 -0.8%	$30.26	$10.83 ▼ $41.14	$3.06B	-0.1	1.46 million shs	2.62 million shs
DNLI Denali Therapeutics	$18.67 -2.6%	$22.47	$13.75 ▼ $27.30	$3.06B	1.02	1.90 million shs	2.37 million shs
LXRX Lexicon Pharmaceuticals	$1.76	$2.15	$1.10 ▼ $2.68	$783.12M	1.07	3.37 million shs	3.32 million shs
RCUS Arcus Biosciences	$23.78 -3.0%	$27.58	$14.26 ▼ $31.74	$3.12B	0.94	1.77 million shs	1.86 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-2.18%	-5.74%	-19.56%	+49.24%	+103.34%
DNLI Denali Therapeutics	-0.62%	-7.31%	-14.00%	-29.58%	+28.59%
LXRX Lexicon Pharmaceuticals	+0.57%	-6.13%	-21.43%	-21.78%	+15.79%
RCUS Arcus Biosciences	+1.00%	-5.26%	-17.31%	-18.31%	+75.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$38.86	42.86% Upside
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.85	92.00% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$5.70	223.86% Upside
RCUS Arcus Biosciences	2.64	Moderate Buy	$38.30	61.08% Upside

Current Analyst Ratings Breakdown

Latest LXRX, DNLI, RCUS, and AMLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$43.00
9/28/2026	LXRX Lexicon Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
9/16/2026	RCUS Arcus Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/11/2026	RCUS Arcus Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/8/2026	RCUS Arcus Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $40.00
8/27/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $57.00
8/25/2026	DNLI Denali Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $35.00
8/19/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $55.00
8/19/2026	AMLX Amylyx Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$28.00 ➝ $52.00
8/18/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $42.00
8/18/2026	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $55.00

(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	34.69	N/A	N/A	$2.78 per share	9.78
DNLI Denali Therapeutics	$330.53M	9.03	N/A	N/A	$6.91 per share	2.70
LXRX Lexicon Pharmaceuticals	$49.80M	15.73	N/A	N/A	$0.30 per share	5.87
RCUS Arcus Biosciences	$247M	12.26	N/A	N/A	$5.84 per share	4.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	11/5/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)

Latest LXRX, DNLI, RCUS, and AMLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	AMLX Amylyx Pharmaceuticals	-$0.3831	N/A	N/A	N/A	$0.06 million	N/A
11/5/2026	Q3 2026	DNLI Denali Therapeutics	-$0.3709	N/A	N/A	N/A	$12.22 million	N/A
11/5/2026	Q3 2026	LXRX Lexicon Pharmaceuticals	-$0.06	N/A	N/A	N/A	$4.15 million	N/A
10/27/2026	Q3 2026	RCUS Arcus Biosciences	-$0.8769	N/A	N/A	N/A	$11.14 million	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
DNLI Denali Therapeutics	0.01	8.37	8.32
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29
RCUS Arcus Biosciences	0.22	3.82	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
DNLI Denali Therapeutics	92.92%
LXRX Lexicon Pharmaceuticals	74.70%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
DNLI Denali Therapeutics	9.70%
LXRX Lexicon Pharmaceuticals	14.00%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
DNLI Denali Therapeutics	507	159.85 million	144.34 million	Optionable
LXRX Lexicon Pharmaceuticals	81	444.96 million	382.66 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable

LXRX, DNLI, RCUS, and AMLX Headlines

Recent News About These Companies

Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?

October 7 at 3:25 PM | finance.yahoo.com

Arcus Biosciences stock fell 3.13 percent on October 2

October 6 at 1:41 PM | ad-hoc-news.deA

Arcus Biosciences stock gains 1.49 percent ahead of data event

October 6 at 1:41 PM | ad-hoc-news.deA

Wall Street Zen upgrades Arcus Biosciences stock to Hold

October 5 at 8:41 AM | ad-hoc-news.deA

How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data

October 4, 2026 | finance.yahoo.com

Arcus Biosciences (NYSE:RCUS) Raised to "Hold" at Wall Street Zen

October 3, 2026 | americanbankingnews.com

Arcus Biosciences (NYSE:RCUS) Stock Moved Up to Hold by Wall Street Zen

October 3, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Earns Outperform Rating from Wedbush

September 30, 2026 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants - September 24, 2026

September 25, 2026 | biospace.comB

Arcus Biosciences stock trades 16.8 percent below yearly high

September 24, 2026 | ad-hoc-news.deA

835,504 Shares in Arcus Biosciences, Inc. $RCUS Bought by Bank of America Corp DE

September 24, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Trading Up 3.2% - Should You Buy?

September 23, 2026 | marketbeat.com

Arcus Biosciences, Inc. Announces New Data for Casdatifan as Treatment for Kidney Cancer Across Multiple Lines of Therapy

September 22, 2026 | marketscreener.comM

Arcus Biosciences (RCUS) Reiterated at Overweight by Cantor Fitzgerald

September 22, 2026 | streetinsider.com

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

September 22, 2026 | finance.yahoo.com

Arcus Biosciences stock holds steady as investors eye latest clinical and earnings signals

September 21, 2026 | ad-hoc-news.deA

Squarepoint Ops LLC Decreases Stake in Arcus Biosciences, Inc. $RCUS

September 21, 2026 | marketbeat.com

TD Cowen Initiates Arcus Biosciences at Buy

September 16, 2026 | marketscreener.comM

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from Analysts

September 16, 2026 | marketbeat.com

Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Arcus Biosciences (NYSE:RCUS) Shares Down 5.6% - Here's What Happened

September 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX, DNLI, RCUS, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$27.20 -0.23 (-0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$27.20 0.00 (0.00%)

As of 07:56 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Denali Therapeutics NASDAQ:DNLI

$18.67 -0.49 (-2.56%)

Closing price 04:00 PM Eastern

Extended Trading

$18.60 -0.07 (-0.37%)

As of 07:30 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.76 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.75 -0.01 (-0.62%)

As of 07:57 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Arcus Biosciences NYSE:RCUS

$23.78 -0.74 (-3.03%)

Closing price 03:59 PM Eastern

Extended Trading

$23.82 +0.04 (+0.18%)

As of 07:56 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LXRX, DNLI, RCUS, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LXRX, DNLI, RCUS, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LXRX, DNLI, RCUS, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX, DNLI, RCUS, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Denali Therapeutics NASDAQ:DNLI

Lexicon Pharmaceuticals NASDAQ:LXRX

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LXRX, DNLI, RCUS, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LXRX, DNLI, RCUS, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LXRX, DNLI, RCUS, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX, DNLI, RCUS, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Denali Therapeutics NASDAQ:DNLI

Lexicon Pharmaceuticals NASDAQ:LXRX

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools